Search

Displaying results 6921 - 6930 of 10000 in total
  1. Drug

    Fucose

    go.drugbank.com/drugs/DB15236
    Investigational

    Fucose is under investigation in clinical trial NCT03354533 (Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II).

  2. Drug

    2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a

    go.drugbank.com/drugs/DB15243
    Investigational

    2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a is under investigation in clinical trial NCT01668823 (Photodynamic Therapy in Treating Patients With Lung Cancer).

  3. Drug

    Ampreloxetine

    go.drugbank.com/drugs/DB15348
    Investigational

    Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

  4. Drug

    Lorukafusp alfa

    go.drugbank.com/drugs/DB15443
    Investigational

    Lorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).

  5. Drug

    Fluzoparib

    go.drugbank.com/drugs/DB15637
    Investigational

    Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

  6. Drug

    Rogaratinib

    go.drugbank.com/drugs/DB15078
    Investigational

    Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).

  7. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season. It is similar to previous mRNA vaccines developed by Moderna (e.g. elasomeran, imelasomeran), but is designed to be effective against the Omicron XBB.1...

  8. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in

  9. Drug

    Opnurasib

    go.drugbank.com/drugs/DB21583
    Investigational

    Opnurasib is under investigation in clinical trial NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer … The usage of the INN stem '-rasib' in the name indicates that Opnurasib is a Ras protein inhibitor.

  10. Drug

    Iseganan

    go.drugbank.com/drugs/DB16010
    Investigational

    Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).